Introduction

This chapter is designed to prepare candidates for the PEBC exams by providing a comprehensive understanding of community-acquired pneumonia (CAP), a prevalent and potentially serious illness encountered in clinical practice. CAP is characterized by key symptoms such as a productive cough, shortness of breath, and fever. Upon physical examination, findings like dullness to percussion and crackles on auscultation, combined with the presence of a new infiltrate on a chest X-ray, help confirm the diagnosis.

The risk factors for developing CAP include extremes of age (very young or elderly), smoking, cardiopulmonary conditions, alcohol dependence, and immunodeficiency. Despite the severity of the condition, approximately 80% of cases are managed effectively in outpatient settings. However, the condition becomes significantly more concerning when hospitalization is required, with mortality rates ranging from 8–10% in general wards to as high as 40% in intensive care units (ICUs).

The clinical presentation of CAP, however, does not typically reveal its exact microbial cause. A variety of microorganisms, including bacteria, viruses, and fungi, are responsible for CAP, with the severity ranging from mild to life-threatening. Notably, Streptococcus pneumoniae is implicated in approximately 50% of cases requiring hospital admission.

A prospective cohort study conducted by the CDC revealed that in about 40% of hospitalized CAP patients, a causative organism was identified. Among these, viruses accounted for 25% of cases, while bacteria were detected in only 10%. The most common pathogens included human rhinovirus (9%), influenza virus (6%), and S. pneumoniae (5%). During the COVID-19 pandemic, co-infections involving bacterial pathogens and SARS-CoV-2 were reported in roughly 7% of cases, highlighting the evolving landscape of respiratory infections and their interplay.

While relatively rare, Mycobacterium tuberculosis (M. tuberculosis) remains an important but often overlooked cause of CAP. This pathogen should be considered in patients with non-resolving pneumonia, particularly those who were born outside of Canada, have HIV or other immunodeficiencies, or reside in long-term care facilities. Additional risk factors include poor housing, crowded living conditions, limited access to nutrition, and specific vulnerabilities observed in First Nations communities. Tuberculosis (TB) should also be suspected in cases unresponsive to standard treatments, necessitating further diagnostic evaluation (see Tuberculosis for detailed guidance).

This chapter focuses exclusively on the diagnosis and treatment of CAP in adults, as pediatric cases are outside its scope. By exploring the clinical presentation, diagnostic approaches, and evidence-based management strategies for CAP, this chapter aims to provide candidates with the essential knowledge required to address this critical condition effectively in both the exam setting and clinical practice.

Pathogens in Community-Acquired Pneumonia (CAP)

Community-acquired pneumonia can be caused by a wide variety of pathogens, which include bacteria, viruses, and occasionally fungi. The following table outlines the key pathogens associated with CAP, emphasizing their potential clinical relevance:

Bacterial Pathogens:

• Streptococcus pneumoniae (most common cause, especially in hospitalized cases)
• Mycoplasma pneumoniae
• Haemophilus influenzae
• Chlamydophila pneumoniae
• Moraxella catarrhalis
• Legionella species
• Mycobacterium tuberculosis complex (rare but significant in high-risk populations)
• Gram-negative bacilli, such as:
  • Escherichia coli
  • Klebsiella species
  • Enterobacter species
  • Serratia species
  • Pseudomonas aeruginosa (seen in immunocompromised or those with structural lung disease)

Viral Pathogens:

• Influenza A and B
• Adenovirus
• Coronavirus species (including SARS-CoV-2)
• Parainfluenza virus
• Respiratory syncytial virus (RSV)
• Human metapneumovirus

Fungal Pathogens (uncommon in CAP, typically seen in immunocompromised individuals): Opportunistic fungal infections, such as those caused by Aspergillus or Cryptococcus species.

Note: CAP may sometimes involve mixed or polymicrobial infections, such as co-infections with viral and bacterial pathogens.

Outcome of Therapy

1. Assess the Severity of Pneumonia to Determine the Appropriate Initial Treatment Setting

   • Ensure timely and accurate assessment using validated tools such as the CURB-65 score or PSI (Pneumonia Severity Index) to determine whether the patient requires outpatient treatment, hospitalization, or admission to an intensive care unit (ICU).
   • For example, a patient with a CURB-65 score of 0–1 may be treated at home, while a score of ≥3 often indicates the need for hospital admission.

2. Relieve Symptoms: Address patient discomfort by targeting the primary symptoms of pneumonia, which may include:

   • Cough (e.g., through antitussives or hydration)
   • Pleuritic chest pain (e.g., with analgesics such as acetaminophen or ibuprofen)
   • Sputum production (e.g., with adequate hydration and mucolytics if necessary)
   • Dyspnea (e.g., with oxygen therapy if hypoxia is present)

3. Prevent Morbidity: Reduce the risk of developing severe complications by early recognition and appropriate management of CAP. Potential complications include:

   • Respiratory failure
   • Pleural effusion
   • Empyema
   • Pulmonary abscess
   • Pneumothorax
   • Sepsis or septic shock
   • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
   • Immobility-related complications (e.g., deep vein thrombosis or pressure ulcers)

4. Prevent Transmission: Implement measures to reduce the spread of infectious agents to others, especially in cases involving highly contagious pathogens like Mycoplasma pneumoniae, Legionella spp., or viral agents such as influenza or SARS-CoV-2. For example, patients should be educated on respiratory hygiene, handwashing, and, if necessary, isolation precautions.

5. Prevent Recurrence: Address underlying risk factors to reduce the likelihood of future episodes of pneumonia:

   • Smoking cessation programs
   • Vaccination (e.g., pneumococcal vaccine and annual influenza vaccination)
   • Optimizing management of comorbid conditions such as diabetes, COPD, or heart failure
   • Encouraging adherence to prescribed antibiotic regimens to avoid incomplete treatment

Assessment of Illness Severity

Accurately assessing the severity of community-acquired pneumonia (CAP) is critical in guiding treatment decisions, including determining whether a patient requires outpatient management, hospitalization, or ICU admission. Two widely used tools for severity assessment are the Pneumonia Severity of Illness (PSI) Score and the CURB-65 Score.

1. Pneumonia Severity of Illness (PSI) Score: The PSI score was developed to predict 30-day mortality among patients with CAP and to assist in making decisions about hospital admission. The score is calculated based on patient characteristics across the following categories:

Demographic Factors:

• Male: Points assigned = age (in years)
• Female: Points assigned = age (in years) minus 10
• Nursing home resident: 10 points

Comorbid Illnesses:

• Neoplastic disease: 30 points
• Liver disease: 20 points
• Heart failure: 10 points
• Cerebrovascular disease: 10 points
• Renal disease: 10 points

Physical Examination Findings:

• Altered mental status: 20 points
• Respiratory rate ≥30 breaths/min: 20 points
• Systolic blood pressure <90 mmHg: 20 points
• Temperature <35°C or >40°C: 15 points
• Pulse >125 beats/min: 10 points

Laboratory Findings:

• Arterial pH <7.35: 30 points
• Blood urea nitrogen >11 mmol/L: 20 points
• Sodium <130 mmol/L: 20 points
• Glucose ≥14 mmol/L: 10 points
• Hematocrit <30%: 10 points
• Partial pressure of arterial oxygen <60 mmHg: 10 points
• Pleural effusion: 10 points

Clinical Application: Patients with a PSI score ≤90 can often be managed as outpatients, whereas those with scores >90 typically require hospital admission. However, clinical judgment remains vital and should override scoring when necessary.

2. CURB-65 Score: The CURB-65 score is a simplified alternative to the PSI score and is commonly used in clinical settings due to its ease of application. It assigns 1 point for each of the following parameters:

1. Confusion (new onset or altered mental status)
2. Urea >7 mmol/L
3. Respiratory rate ≥30 breaths/min
4. Systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg
5. Age ≥65 years

Risk Stratification and Mortality Predictions:

1. 0–1 Points: Low risk (<0.6% mortality); suitable for outpatient management.
2. 2 Points: Moderate risk (mortality ~6%); consider hospitalization.
3. 3–5 Points: High risk (mortality up to 57%); hospitalization or ICU admission required.

CRB-65 Score: A modified version of the CURB-65 (excluding the urea criterion) may be used in resource-limited settings or where laboratory results are unavailable. Despite its simplicity, it effectively predicts patient outcomes.

Therapeutic Choices in Community-Acquired Pneumonia

Successful management of CAP is predicated on an accurate assessment of illness severity (see Assessment of Illness Severity) and the selection of the most appropriate pharmacologic treatment. This section provides an overview of empiric therapy, antibiotic selection based on specific pathogens, and considerations for treatment.

---

Pharmacologic Choices

1. Empiric Therapy

Empiric antibiotic therapy is guided by clinical presentation, severity, and local epidemiologic patterns. Evidence from systematic reviews and randomized controlled trials suggests the following:

• For outpatients, first-line options include:

• Amoxicillin (preferred as monotherapy)

• Amoxicillin/clavulanate or doxycycline as second-line choices

• Macrolides (e.g., azithromycin, clarithromycin) can be used if resistance patterns allow, but caution is advised due to risks of QT interval prolongation.

• For inpatients with severe pneumonia, combination therapy with:

• A third-generation cephalosporin (e.g., ceftriaxone or cefotaxime) plus a macrolide (e.g., azithromycin or clarithromycin)

• Alternatively, respiratory fluoroquinolones (e.g., levofloxacin) may be used.

• In cases with a high risk of resistant pathogens (e.g., Pseudomonas aeruginosa), consider using piperacillin/tazobactam or another broad-spectrum beta-lactam, particularly in patients with recent hospitalization or prior respiratory isolation of resistant pathogens.

If the causative pathogen is identified, therapy should be tailored based on culture and sensitivity results.

---

2. Antibiotic Therapy by Specific Pathogens

Table 3 highlights the recommended antibiotic regimens for CAP based on specific pathogens:

---

3. Considerations for Therapy

• Resistance Management: Avoid overuse of fluoroquinolones to prevent resistance and adverse effects such as QT prolongation.

• Pathogen-Specific Factors: Tailor therapy to specific organisms and consider local susceptibility patterns, including the presence of outbreaks or endemic pathogens.

• Patient-Specific Factors: Consider comorbidities, age, and recent antibiotic exposure when selecting a regimen.

Key Clinical Considerations and Management of CAP

1. Duration of Antibiotic Therapy

• For ambulatory patients responding well to treatment, the recommended duration of antibiotic therapy is 5–7 days.
• For hospitalized patients who become afebrile within 48 hours and exhibit no more than one sign of clinical instability, 5 days of therapy is often sufficient.
• Longer durations are necessary for specific complications:
  • Severe Legionnaires' disease: 21 days
  • Bacteremic pneumonia caused by aerobic gram-negative bacilli or Pseudomonas aeruginosa: 7–10 days
  • Empyema: Requires drainage and prolonged treatment for at least 14 days.
  • Lung abscesses: Therapy may extend up to 12–16 weeks until the cavity resolves.

---

2. Aspiration Pneumonia

• Aspiration pneumonia involves infection resulting from the inhalation of oropharyngeal or gastric contents into the lungs.
• Risk factors include:
  • Reduced level of consciousness
  • Neurologic diseases (e.g., stroke, impaired swallowing)
  • Impaired glottic closure
• Management:
  • Routine anaerobic coverage is not recommended unless there is a lung abscess or empyema.
  • Treatment aligns with standard CAP therapy.

---

3. Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia

• MRSA is an uncommon cause of CAP but accounts for 1–5% of cases, primarily in:
  • ICU patients
  • Residents of long-term care facilities
• Treatment:
  • Effective options include vancomycin and linezolid.
  • Daptomycin should be avoided in pneumonia due to inactivation by pulmonary surfactant.
• Special Considerations:
  • Suspect endocarditis in cases of bacteremic S. aureus pneumonia, especially with multiple rounded opacities on chest X-ray.

---

4. Corticosteroid Use in CAP

• Corticosteroids may benefit patients with severe CAP by reducing:
  • All-cause mortality
  • Risk of acute respiratory distress syndrome (ARDS)
  • Length of hospital stay
• Regimens include:
  • Prednisone 50 mg PO daily for 7 days
  • Methylprednisolone 0.5 mg/kg BID IV for 5 days
• Corticosteroids are generally reserved for patients with severe CAP, guided by validated scales and clinical judgment.

---

5. COVID-19 Pneumonia

• Bacterial co-infection in COVID-19 is rare, occurring in approximately 7% of cases.
• Antibiotics should not be routinely prescribed in mild or moderate COVID-19 unless bacterial co-infection is suspected.
• Empiric antibiotic use should be reassessed within 3 days to ensure appropriate escalation or de-escalation.

---

6. Influenza Pneumonia

• Groups at high risk for complications include:
  • Older adults
  • Pregnant patients
  • Indigenous populations
  • Individuals with comorbidities
• Studies suggest bacterial co-infection (e.g., S. pneumoniae, S. aureus) occurs in up to 55% of fatal cases.
• Antiviral therapy (e.g., oseltamivir) should be initiated promptly for hospitalized patients, even if symptoms have persisted beyond 48 hours.

Prevention of Community-Acquired Pneumonia

Effective prevention strategies play a critical role in reducing the incidence and complications associated with CAP. The following approaches focus on modifiable risk factors and evidence-based interventions.

---

1. Smoking Cessation

Smoking is associated with a two-fold increased risk of invasive pneumococcal pneumonia, likely due to its negative impact on lung function and the immune response.

• Recommendation: Encourage cessation of tobacco use (refer to resources such as Tobacco Use Disorder: Smoking Cessation). While clinical trials specifically linking smoking cessation to reduced pneumonia risk are lacking, significant benefits include:

• Slowing age-related decline in lung function

• Reducing the risk of lung cancer and respiratory infections

• Minimizing second-hand smoke exposure for household members

---

2. Vaccines

a. Influenza Vaccine

• Who Should Receive It: Annual vaccination is recommended for everyone over 6 months of age, especially those at high risk, including older adults, pregnant individuals, Indigenous populations, and individuals with comorbidities.

• Benefits:

• Reduces hospital admissions for pneumonia and heart failure

• Demonstrated a 51% reduction in mortality during influenza seasons among high-risk patients

• Immunizing healthcare workers reduces morbidity and mortality among patients and staff

• Efficacy: Studies show a 40% reduction in pneumonia cases with influenza vaccination during the flu season.

b. Pneumococcal Vaccine

Two types of pneumococcal vaccines are available in Canada:

1. Polysaccharide Vaccine (PNEU-P-23):

• Covers 23-valent capsular types of Streptococcus pneumoniae.

• Shown to reduce mortality and ICU admissions among hospitalized CAP patients.

2. Conjugate Vaccines (PNEU-C-13, PNEU-C-15, PNEU-C-20):

• Enhance immunogenicity by linking polysaccharides to a protein carrier.

• Reduce invasive pneumococcal disease and bacteremic pneumonia.

• Canadian Recommendations:

• PNEU-C-20 is recommended for adults ≥65 years or those with risk factors (e.g., immunocompromised, chronic disease).

• Sequential administration of PNEU-C-13 followed by PNEU-P-23 is an alternative strategy.

Special Considerations:

• Vaccination is critical for those who have undergone hematopoietic stem cell transplants or who reside in long-term care facilities.

---

3. Prevention of Aspiration Pneumonia

Aspiration pneumonia results from the inhalation of oropharyngeal or gastric contents into the lungs, often in individuals with swallowing impairments.

• Risk Reduction Strategies:

• Encourage the "chin-down" posture during swallowing to decrease aspiration.

• Elevate the head of the bed to at least 30 degrees.

• Enhance oral care, especially in patients with dysphagia or poor dentition.

• Interventions such as modifying diet consistency and providing swallowing therapy can also help.

Evidence Base: Although specific evidence on posture modification is limited, these measures are widely recommended to reduce aspiration risk in vulnerable populations.

Therapeutic notes for Community-Acquired Pneumonia

The following tips provide practical guidance to enhance the management of CAP, focusing on evidence-based practices and patient-centered care:

---

1. Empiric Therapy

• Antibiotic Class Rotation: If the patient has received antibiotics in the past three months, select an agent from a different therapeutic class to reduce the risk of resistance.
• Avoid Erythromycin in COPD: Due to its limited activity against Haemophilus influenzae, erythromycin is not recommended for empiric therapy in patients with COPD.

---

2. Outpatient Therapy

• No Clear Superiority Among Agents: Most randomized controlled trials comparing antibiotics for outpatient CAP show no significant differences in outcomes.
• Shortened Hospital Stays: Evidence from randomized trials suggests that early mobilization and proper antibiotic management can reduce hospitalization length for CAP patients.

---

3. Atypical Pathogen Coverage

• Despite guidelines recommending coverage for atypical pathogens (e.g., Mycoplasma pneumoniae, Chlamydophila pneumoniae), there is no conclusive evidence that regimens including such coverage improve outcomes compared to those without it.

---

4. Switching from Parenteral to Oral Therapy

Consider transitioning from IV to oral antibiotics when all the following criteria are met:

• Stable GI Function: No vomiting, diarrhea, or GI absorption disorders.
• Hemodynamic Stability: Normalized vital signs.
• Afebrile State: Two normal temperature readings (<37.5°C) over 16 hours in a previously febrile patient.
• Improved Symptoms: Reduction in cough and shortness of breath.
• Normalized Lab Markers: White blood cell count returning to normal.
• Oral Tolerance: Ability to consume oral medications.

---

5. Blood Cultures and Duration of IV Therapy

• If blood cultures are positive, the duration of IV therapy should align with the organism identified and its susceptibility profile.
• Early switching to oral therapy and mobilization can significantly reduce hospital stay lengths.

---

6. Criteria for Discharge

Patients can be discharged when the following criteria are met:

1. Resolution of Pneumonia-Related Complications: No empyema or ongoing symptoms.
2. Absence of Comorbid Complications: Conditions such as myocardial infarction (MI) are stabilized.
3. No Treatment Complications: No severe adverse drug reactions or allergies.
4. Physiological Stability:
   • Oxygen saturation ≥92% on room air.
   • Pulse rate <100 beats/min.
   • Respiratory rate ≤24 breaths/min.
   • For patients with COPD, a return to baseline respiratory status is necessary.

---

7. Prevention of Recurrent Pneumonia

• In individuals ≥65 years of age or those with recurrent episodes, identify risk factors such as aspiration or immunodeficiency and implement appropriate preventive measures.
• Vaccination Status: Review and update pneumococcal and influenza vaccines if indicated.